Nanoparticle orientation offers a way to enhance drug delivery

November 05, 2019

CAMBRIDGE, MA -- MIT engineers have shown that they can enhance the performance of drug-delivery nanoparticles by controlling a trait of chemical structures known as chirality -- the "handedness" of the structure.

Many biological molecules can come in either right-handed or left-handed forms, which are identical in composition but are mirror images of each other.

The MIT team found that coating nanoparticles with the right-handed form of the amino acid cysteine helped the particles to avoid being destroyed by enzymes in the body. It also helped them to enter cells more efficiently. This finding could help researchers to design more effective carriers for drugs to treat cancer and other diseases, says Robert Langer, the David H. Koch Institute Professor at MIT and a member of the Koch Institute for Integrative Cancer Research.

"We are very excited about this paper because controlling chirality offers new possibilities for drug delivery and hence new medical treatments," says Langer, who is one of the senior authors of the paper.

Ana Jaklenec, a research scientist at the Koch Institute, is also a senior author of the paper, which appears in Advanced Materials on Nov. 4. The paper's lead author is MIT postdoc Jihyeon Yeom. Other authors of the paper are former MIT postdocs Pedro Guimaraes and Kevin McHugh, MIT postdoc Quanyin Hu, and Koch Institute research affiliate Michael Mitchell. Hyo Min Ahn, BoKyeong Jung, and Chae-Ok Yun of Hanyang University in Seoul, South Korea, are also authors of the paper.

Chiral interactions

Many biologically important molecules have evolved to exist exclusively in either right-handed ("D") or left-handed ("L") versions, also called enantiomers. For example, naturally occurring amino acids are always "L" enantiomers, while DNA and glucose are usually "D."

"Chirality is ubiquitous in nature, imparting uniqueness and specificity to the biological and chemical properties of materials," Yeom says. "For example, molecules formed with the same composition taste sweet or bitter and smell differently depending on their chirality, and one enantiomer is inactive or even toxic while the other enantiomer can serve an important biological function."

The MIT team hypothesized that it might be possible to take advantage of chiral interactions to improve the performance of drug-delivery nanoparticles. To test that idea, they created "supraparticles" consisting of clusters of 2-nanometer cobalt oxide particles whose chirality was provided by either the "D" or "L" version of cysteine on the surfaces.

By flowing these particles along a channel lined with cancer cells, including myeloma and breast cancer cells, the researchers could test how well each type of particle was absorbed by the cells. They found that particles coated with "D" cysteine were absorbed more efficiently, which they believe is because they are able to interact more strongly with cholesterol and other lipids found in the cell membrane, which also have the "D" orientation.

The researchers also believed that the "D" version of cysteine might help nanoparticles avoid being broken down by enzymes in the body, which are made of "L" amino acids. This could allow the particles to circulate in the body for longer periods of time, making it easier for them to reach their intended destinations.

In a study of mice, the researchers found that "D"-coated particles did stay in the bloodstream longer, suggesting that they were able to successfully evade enzymes that destroyed the "L"-coated particles. About two hours after injection, the number of "D" particles in circulation was much greater than the number of "L" particles, and it remained higher over the 24 hours of the experiment.

"This is a first step in looking at how chirality can potentially aid these particles in reaching cancer cells and increasing circulation time. The next step is to see if we could actually make a difference in cancer treatment," Jaklenec says.

Modified particles

The researchers now plan to test this approach with other types of drug-delivery particles. In one project, they are investigating whether coating gold particles with "D" amino acids will improve their ability to deliver cancer drugs in mice. In another, they are using this approach to modify adenoviruses, which some of their collaborators are developing as a potential new way to treat cancer.

"In this study, we showed that the 'D' chirality allows for longer circulation time and increased uptake by cancer cells. The next step would be to determine if drug-loaded chiral particles give enhanced or prolonged efficacy compared to free drug," Jaklenec says. "This is potentially translatable to essentially any nanoparticle."
-end-
The research was funded by the Koch Institute's Marble Center for Cancer Nanomedicine, the National Council for Scientific and Technological Development of Brazil, the Estudar Foundation, a Ruth L. Kirschstein National Research Service Award, a Burroughs Wellcome Fund Career Award at the Scientific Interface, an National Institutes of Health Director's New Innovator Award, the American Cancer Society, an AACR-Bayer Innovation and Discovery Grant, and the National Research Foundation of Korea.

Massachusetts Institute of Technology

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.